FDA asks for comments on process for implementing label reform regs.
This article was originally published in The Tan Sheet
Executive Summary
FDA SEEKS COMMENTS ON PROCESS FOR IMPLEMENTING LABEL REFORM REGS in a Sept. 14 correction to the Aug. 16 Federal Register notice announcing the upcoming public hearing on drug labeling scheduled for Sept. 29. Calling revision of the labeling sections of the monographs a "major undertaking," the agency announced that it is seeking comments on "the process that should be followed by FDA to ensure that the revisions are completed in an efficient and expedient manner." The request for public comment was "inadvertently omitted" from the Aug. 16 notice.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning